More Evidence Needed For Chiesi’s Ultra Orphan Lamzede, Says NICE

Chiesi still has work to do to convince NICE that its ultra rare disease treatment Lamzede is a cost-effective treatment.

Doctor holding out your piggy bank wanting payment/ Your Savings To Pay Bill, insert coins to it,Stethoscope financial checkup or saving for medical insurance costs money plan fee Lifestyle concept — NICE not sure Chiesi's Lamzede is cost-effective • Source: Scrip archive

Chiesi could have its work cut out to persuade NICE, the health technology appraisal institute for England and Wales, that its enzyme replacement therapy Lamzede (velmanase alfa) is a cost-effective treatment for the ultra rare condition alpha-mannosidosis. The institute this week published draft guidance stating that it had too many doubts about the available evidence and the company’s economic modelling.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Spruce Pivots After Pipeline Failure With BioMarin Tralesinidase Deal

17 Apr 2025

• By Sushmita Panda

After dropping its lead program in December, Spruce has been exploring strategic options – and thinks it has a de-risked path for MPS IIIB therapy tralesinidase from BioMarin.

Glycomine Funds Phase IIb Rare Disease Trial With $115m Series C

16 Apr 2025

• By Mandy Jackson

Lead drug GLM101 will move into its first placebo-controlled trial based on positive results in adults and adolescents with PMM2-CDG in an open-label Phase IIa study.

New Data Strengthen Case For RemeGen’s Telitacicept In gMG

10 Apr 2025

• By Dexter Jie Yan

Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.

Vocal For ‘Glocal’: How Menarini Is Adapting To Outperform In The Asia Pacific

08 Apr 2025

• By Anju Ghangurde

Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.